Comparative Pharmacology
Head-to-head clinical analysis: CYKLOKAPRON versus NUMBRINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYKLOKAPRON versus NUMBRINO.
CYKLOKAPRON vs NUMBRINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Selective serotonin reuptake inhibitor (SSRI); increases synaptic serotonin by inhibiting SERT.
1 g (10 mL) IV over 5-10 minutes every 6-8 hours; or 25-50 mg/kg/day IV divided every 6-8 hours. Oral: 1-1.5 g 3-4 times daily.
2 mg/kg intravenously every 8 hours, max 150 mg per dose.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (renal impairment extends to 10-20 hours).
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min)
Renal: >95% as unchanged drug via glomerular filtration; minimal biliary/fecal (<5%).
Renal: 70% unchanged; hepatic metabolism: 20%; fecal: 10%
Category C
Category C
Antifibrinolytic
Antifibrinolytic